Abstract:Background: Obstructive sleep apnea (OSA) is an independent risk factor for cardiovascular (CV) morbidity and mortality, but the benefit of continuous positive airway pressure (CPAP) therapy is uncertain. However, most randomized-controlled trials have focused on the role of CPAP in secondary prevention although there is growing evidence of a potential benefit on early CV disease. Weight loss in combination with CPAP may be superior but is difficult to achieve and maintain with conventional measures alone. The aim of this study was to gain insights into the effect of CPAP on early atherosclerotic processes and to compare it to a glucagon-like-peptide (GLP)-1-mediated weight loss regimen in OSA. Methods: We performed a randomized proof-of-concept study (clinicaltrials.gov: NCT04186494) comparing CPAP, a liraglutide-based weight loss regimen (Lir) alone or both in combination for 24 weeks in 30 non-diabetic patients with moderate to severe OSA (50{+/-}7 years, 80% males, apnea-hypopnea index [AHI] 50{+/-}19/hr, body mass index [BMI] 35.0 {+/-}3 kg/m2). Baseline characteristics were similar between groups. Beside extensive evaluation for CV risk factors and endothelial function at baseline and end of study, subjects underwent 18F-fluorodeoxyglucose (FDG)-PET-CT for measurement of aortic wall inflammation (target-to-background ratio [TBR]) and coronary CT angiography (CCTA) for semi-automated coronary plaque analysis. Results: CPAP alone and combination resulted in greater reduction in AHI than Lir alone at 24 weeks (mean difference -45/hr and -43/hr, respectively, vs -12/hr, p<0.05). Both Lir and combination led to significant weight loss of 6{+/-}3% and 4{+/-}4%, respectively. Despite CPAP resulting in small weight gain, only the CPAP alone group demonstrated a significant decrease in vascular inflammation (aortic wall TBR from 2.03{+/-}0.34 to 1.84{+/-}0.43, p 0.010) associated with improvement in endothelial function and decrease in C-reactive protein. Low-attenuation coronary artery plaque volume as marker of unstable plaque also decreased with CPAP (from 571{+/-}490 to 334{+/-}185mm3) and with combination therapy (from 401{+/-}145 to 278{+/-}126mm3) but not with Lir. Conclusion: These data suggest that CPAP therapy, but not GLP-1 mediated weight loss, improves vascular inflammation and reduces low-attenuation coronary artery plaque volume in OSA patients. These novel findings support the benefit of CPAP therapy in modifying early CV disease.

Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials

Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea

Impact of long-term continuous positive airway pressure on liver fat in male obstructive sleep apnea patients with fatty liver

Treating Obstructive Sleep Apnea and Chronic Intermittent Hypoxia Improves the Severity of Nonalcoholic Fatty Liver Disease in Children

Effect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis

Impact of Continuous Positive Airway Pressure Treatment on Left Ventricular Ejection Fraction in Patients with Obstructive Sleep Apnea: a Meta-Analysis of Randomized Controlled Trials.

Association between non-alcoholic fatty liver disease and obstructive sleep apnea

Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea

Continuous positive airway pressure but not Liraglutide-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: Data from a randomized proof-of-concept study.

Effect of Continuous Positive Airway Pressure on Lipid Profile in Patients with Obstructive Sleep Apnea Syndrome: a Meta-Analysis of Randomized Controlled Trials.

Impact of continuous positive airway pressure on cognitive functions in adult patients with obstructive sleep apnea: A systematic review and meta-analysis

Effects of Continuous Positive Airway Pressure on Neurocognitive Architecture and Function in Patients with Obstructive Sleep Apnoea: Study Protocol for A Multicentre Randomised Controlled Trial

Influence of Continuous Positive Airway Pressure Treatment on Cardiovascular Risk Factors in Patients with Obstructive Sleep Apnea-Hypopnea Syndrome

Effects of Continuous Positive Airway Pressure Treatment on Vascular Function in a Real-Life Cohort of Elderly Patients with Obstructive Sleep Apnoea Syndrome

Association of Obstructive Sleep Apnea with Nonalcoholic Fatty Liver Disease: Evidence, Mechanism, and Treatment

Effect of Continuous Positive Airway Pressure on Prothrombotic Markers in Obstructive Sleep Apnea and Hypopnea Syndrome Patients: A Meta-analysis

Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep apnea: a meta-analysis

Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: Systematic review and meta-analysis

Efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease and obstructive sleep apnea; a randomized controlled trial

Continuous Positive Airway Pressure Therapy and Long-Term Outcomes in Patients with Coronary Artery Disease and Obstructive Sleep Apnea: A Meta-Analysis of Randomized Trials

Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis